Can reprogrammed immune cells take on hard-to-treat kidney cancer?
NCT ID NCT06586658
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-phase trial is testing a therapy called anti-CD70 CAR-T cells in people with advanced kidney cancer that has not responded to standard treatments. The approach involves taking a patient's own immune cells, engineering them in a lab to recognize a protein called CD70 on cancer cells, and infusing them back to attack the tumor. The study aims to determine the safest dose and whether this cell therapy can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a patient's own immune cells engineered to recognize and attack CD70 on kidney cancer cells
- What this could lead to
- If successful, this approach could offer a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial (9 people) focused on safety. CAR-T therapy can cause severe side effects like cytokine release syndrome, and it may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Robot surgeon takes on kidney and prostate operations
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- AI model aims to predict recovery after Kidney-Sparing surgery
- Lab-Made immune protein takes on advanced cancers in first human test